CDXC - ChromaDex Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.5600
-0.2300 (-4.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.7900
Open4.7400
Bid4.2000 x 1100
Ask4.5500 x 1400
Day's Range4.5500 - 4.7600
52 Week Range2.7900 - 5.0000
Volume135,914
Avg. Volume201,080
Market Cap253.179M
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.6020
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.17
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference

    ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients.

  • ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript
    Motley Fool6 days ago

    ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript

    CDXC earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of CDXC earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Chromadex Corp Earnings Call

  • ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
    Zacks10 days ago

    ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

    ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press10 days ago

    ChromaDex: 1Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of 15 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The natural products company posted revenue of $10 million in ...

  • GlobeNewswire10 days ago

    ChromaDex Corporation Reports First Quarter 2019 Financial Results

    - First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net.

  • GlobeNewswire10 days ago

    ChromaDex Announces $10 Million Issuance of Convertible Notes

    ChromaDex Corp. (CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The convertible notes will automatically convert into shares of ChromaDex common stock 45 days following the closing.  The convertible notes will convert at $4.59 per share (market closing price on May 7, 2019), or if a common stock financing occurs in the 45 day period following the closing with a purchase price of less than $4.59 per share, at the price per share at which shares are issued in that financing.

  • Should You Be Concerned About ChromaDex Corporation's (NASDAQ:CDXC) Historical Volatility?
    Simply Wall St.12 days ago

    Should You Be Concerned About ChromaDex Corporation's (NASDAQ:CDXC) Historical Volatility?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in ChromaDex Corporation (NASDAQ:CDXC), then you might want to consider its beta...

  • Will ChromaDex (CDXC) Report Negative Q1 Earnings? What You Should Know
    Zacks17 days ago

    Will ChromaDex (CDXC) Report Negative Q1 Earnings? What You Should Know

    ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire18 days ago

    ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

    LOS ANGELES, May 02, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its.

  • GlobeNewswire26 days ago

    ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies

    ChromaDex Corp. (CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (WELL.V) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other allied health businesses. According to Orbis Research, the $250 billion emerging anti-aging category is expected to reach some $331 billion by the year 2021, with rapid growth fueled by advancements in science and technology, and an aging global population. “Given the size of the global market, and the access to a key influencer group in British Columbia, we believe this partnership is an important milestone in our global expansion strategy,” said ChromaDex CEO Rob Fried.

  • GlobeNewswirelast month

    ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada

    ChromaDex Corp. (CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the greater Toronto area as well as Showcase’s online store. “Tru Niagen appeals to health-conscious and high-performing consumers seeking products for a better life—this makes it a natural fit for Showcase, which attracts discerning customers seeking innovative products and emerging brands," said ChromaDex CEO Rob Fried.

  • Business Wirelast month

    New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)

    ChromaDex Corp. (CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved cellular response called the “mitochondrial unfolded protein response” (UPRmt) that helps maintain mitochondrial function. The study also presents preliminary human data to support future testing of NR in humans.

  • Volatility 101: Should ChromaDex (NASDAQ:CDXC) Shares Have Dropped 17%?
    Simply Wall St.last month

    Volatility 101: Should ChromaDex (NASDAQ:CDXC) Shares Have Dropped 17%?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! While not a mind-blowing move, it is good to see that the ChromaDex Corporation (NASDAQ:CDXC) share price has gained 23% i...

  • GlobeNewswire2 months ago

    Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP’s Sixth Annual Biohacking Conference

    ChromaDex Corp. (CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking Conference, a three-day immersive experience for the human performance industry.  Hosted by Upgrade Labs, the conference runs Friday, April 5 through Sunday, April 7, 2019 at the Beverly Hilton Hotel in Los Angeles. The breakout session will explain cellular metabolism and the role of NAD as a key coenzyme in electron transport, which plays a crucial role in energy production for the body. Dr. Brenner will also reveal how metabolic stressors can compromise one’s NAD pool and why optimal NAD levels are important to enjoy a more resilient life.

  • GlobeNewswire2 months ago

    Consolidated Research: 2019 Summary Expectations for Vishay Intertechnology, Belmond, Silicon Motion Technology, Ardmore Shipping, Northwest Pipe, and ChromaDex — Fundamental Analysis, Key Performance Indications

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CDXC earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Chromadex Corp Earnings Call

  • GlobeNewswire2 months ago

    ChromaDex to Present at the 31st Annual ROTH Conference

    ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. For more information about the conference or to schedule a one-on-one meeting with ChromaDex management, please contact your ROTH representative.

  • GlobeNewswire2 months ago

    ChromaDex Brings TRU NIAGEN® to SXSW® 2019

    ChromaDex Corp. (CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide riboside) ingredient. "To help SXSW® attendees who need an extra boost in their busy lives, we'll be providing samples of Tru Niagen and discussing the science that disrupted the multi-billion-dollar anti-aging category with the discovery of nicotinamide riboside by Dr. Charles Brenner," says Frank Jaksch, ChromaDex Co-Founder and Executive Chairman.

  • GlobeNewswire2 months ago

    ChromaDex Corporation Reports 2018 Financial Results

    - Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs..

  • GlobeNewswire3 months ago

    ChromaDex to Present at the 39th Annual Cowen Health Care Conference

    ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA. The ChromaDex management team is scheduled to present on Monday, March 11, at 4:50 p.m. ET. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day.

  • GlobeNewswire3 months ago

    ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

    LOS ANGELES, Feb. 28, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its.

  • Why ChromaDex Corporation (NASDAQ:CDXC) Could Be Worth Watching
    Simply Wall St.3 months ago

    Why ChromaDex Corporation (NASDAQ:CDXC) Could Be Worth Watching

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! ChromaDex Corporation (NASDAQ:CDXC), which is in the life sciences business,Read More...

  • GlobeNewswire4 months ago

    New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

    ChromaDex Corp. (CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conducted at the University of Iowa by Principal Investigator Dr. Charles Brenner, the Roy J. Carver Chair & Head of Biochemistry at the University of Iowa, as well as a founding co-director of the University of Iowa Obesity Initiative and Chief Scientific Advisor of ChromaDex, the study results were published yesterday in the journal Cell Reports.